Phenylketonuria (PKU) is a rare, inherited metabolic condition defined by a lack of the enzyme phenylalanine hydroxylase (PAH). Because PKU is an inherited disorder, a genetic risk assessment and precision medicine evaluation can help families understand inheritance patterns, recurrence risk, and personalized long-term management strategies. The enzyme, responsible for transforming one of the essential building blocks of protein (an amino acid), into another (called tyrosine), is not sufficiently active in individuals with PKU. This leaves the amino acid phenylalanine (Phe), found in most protein-foods and some artificial sweeteners, building up to harmful levels in blood and brain. 

A rare genetic disorder, PKU is inherited through autosomal recessive means. Families affected by inherited conditions may benefit from a hereditary disease evaluation through precision medicine, particularly when planning future pregnancies or assessing risks for other relatives. For a child to be born with PKU, both parents need to contribute one copy of the faulty PAH gene; simply having a single copy doesn’t pose a threat. 

If PKU remains undetected, excessive quantities of phenylalanine can cause severe, irreversible intellectual impairment, as well as epilepsy, developmental problems, eczema, and a specific body odour. Fortunately, thanks to systematic newborn testing programs implemented in many wealthy nations, a diagnosis in many infants takes place within their first few days, before brain damage occurs, allowing treatment to begin without delay. Early diagnosis is only the first step, and a comprehensive medical assessment for inherited metabolic disorders can help determine baseline health, nutritional status, and ongoing monitoring needs.